• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Salvage therapy with decitabine in combination with granulocyte colony-stimulating factor, low-dose cytarabine, and aclarubicin in patients with refractory or relapsed early T-cell precursor acute lymphoblastic leukemia.

作者信息

Meng Tongyan, Yao Yao, Xu Yang, Xue Shengli, Han Yue, Tang Xiaowen, Qiu Huiying, Sun Aining, Wu Depei, Zhang Yanming, Wang Ying

机构信息

National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China.

Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.

出版信息

Hematol Oncol. 2020 Dec;38(5):834-837. doi: 10.1002/hon.2783. Epub 2020 Aug 14.

DOI:10.1002/hon.2783
PMID:32710795
Abstract
摘要

相似文献

1
Salvage therapy with decitabine in combination with granulocyte colony-stimulating factor, low-dose cytarabine, and aclarubicin in patients with refractory or relapsed early T-cell precursor acute lymphoblastic leukemia.地西他滨联合粒细胞集落刺激因子、小剂量阿糖胞苷和阿柔比星对难治性或复发性早期T细胞前体急性淋巴细胞白血病患者进行挽救治疗。
Hematol Oncol. 2020 Dec;38(5):834-837. doi: 10.1002/hon.2783. Epub 2020 Aug 14.
2
Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.低剂量阿糖胞苷和阿克拉霉素联合粒细胞集落刺激因子（CAG 方案）与 Hyper-CVAD 方案在复发/难治性费城染色体阴性急性淋巴细胞白血病中的疗效比较。
Leuk Res. 2015 Mar;39(3):323-8. doi: 10.1016/j.leukres.2015.01.003. Epub 2015 Jan 16.
3
Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.西达本胺、地西他滨、阿糖胞苷、阿克拉霉素和粒细胞集落刺激因子（CDCAG）治疗复发/难治性急性髓系白血病患者：单臂、1/2 期研究。
Clin Epigenetics. 2020 Sep 1;12(1):132. doi: 10.1186/s13148-020-00923-4.
4
Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.在小剂量阿糖胞苷与阿柔比星联合粒细胞集落刺激因子（CAG方案）中增加阿柔比星剂量，作为复发/难治性混合表型急性白血病的挽救化疗是有效的。
Leuk Res. 2015 Aug;39(8):805-11. doi: 10.1016/j.leukres.2015.04.006. Epub 2015 Apr 20.
5
Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.小剂量阿糖胞苷和阿克拉霉素联合粒细胞集落刺激因子治疗复发或原发性难治性急性淋巴细胞白血病：25 例中国患者的回顾性研究。
Hematol Oncol. 2013 Dec;31(4):206-12. doi: 10.1002/hon.2051. Epub 2013 Apr 25.
6
[Treatment of relapsed and refractory acute lymphocytic leukemia by modified CAG regimen].改良CAG方案治疗复发难治性急性淋巴细胞白血病
Zhonghua Xue Ye Xue Za Zhi. 2016 Apr;37(4):340-2. doi: 10.3760/cma.j.issn.0253-2727.2016.04.019.
7
CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study.CAG 方案治疗难治或复发成人 T 细胞急性淋巴细胞白血病：一项回顾性、多中心队列研究。
Cancer Med. 2020 Aug;9(15):5327-5334. doi: 10.1002/cam4.3079. Epub 2020 Jun 3.
8
Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.克拉屈滨联合粒细胞集落刺激因子、阿糖胞苷和阿克拉霉素治疗难治/复发急性髓系白血病的 II 期多中心研究。
Oncologist. 2020 Nov;25(11):e1663-e1670. doi: 10.1634/theoncologist.2020-0818. Epub 2020 Sep 21.
9
Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia.增加阿克拉霉素在小剂量阿糖胞苷与阿克拉霉素联合粒细胞集落刺激因子（CAG方案）中的剂量，可安全有效地治疗复发或难治性急性髓系白血病。
Int J Hematol. 2014;99(5):603-8. doi: 10.1007/s12185-014-1528-8. Epub 2014 Mar 13.
10
Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with l-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia.粒细胞集落刺激因子、小剂量阿糖胞苷和阿柔比星联合左旋门冬酰胺酶、泼尼松治疗难治性或复发性急性淋巴细胞白血病的疗效与安全性
Leuk Res. 2017 Nov;62:29-33. doi: 10.1016/j.leukres.2017.09.016. Epub 2017 Sep 25.

引用本文的文献

1
Mechanism of action of decitabine in treating acute lymphoblastic leukemia.地西他滨治疗急性淋巴细胞白血病的作用机制。
Front Med (Lausanne). 2025 Jul 30;12:1614592. doi: 10.3389/fmed.2025.1614592. eCollection 2025.
2
Promising Drugs Targeting Specific Mechanisms of Deregulation in T Cell Lineage Acute Lymphoblastic Leukemia.针对T细胞系急性淋巴细胞白血病特定失调机制的有前景的药物
Oncol Ther. 2025 Apr 18. doi: 10.1007/s40487-025-00339-1.
3
Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and aclarubicin for salvage therapy of relapsed/refractory T cell acute lymphoblastic leukemia.
维奈托克与阿扎胞苷联合高三尖杉酯碱、阿糖胞苷和阿柔比星用于复发/难治性T细胞急性淋巴细胞白血病的挽救治疗。
Int J Hematol. 2025 Apr;121(4):547-552. doi: 10.1007/s12185-025-03915-3. Epub 2025 Jan 23.
4
Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax.DNA 高甲基化导致 miR-182 表达降低，通过靶向 PBX3 和 BCL2 加速急性淋巴细胞白血病的发展：miR-182 启动子甲基化是低甲基化剂+BCL2 抑制剂 venetoclax 的预测标志物。
Clin Epigenetics. 2024 Mar 26;16(1):48. doi: 10.1186/s13148-024-01658-2.
5
Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review.维奈克拉联合 CAG 方案治疗早幼粒细胞性急性淋巴细胞白血病 1 例报告并文献复习
Int J Hematol. 2023 Oct;118(4):483-488. doi: 10.1007/s12185-023-03623-w. Epub 2023 Jun 3.
6
Early T-Cell Precursor Acute Lymphoblastic Leukemia: Diagnosis, Updates in Molecular Pathogenesis, Management, and Novel Therapies.早期T细胞前体急性淋巴细胞白血病：诊断、分子发病机制的进展、管理及新疗法
Front Oncol. 2021 Nov 29;11:750789. doi: 10.3389/fonc.2021.750789. eCollection 2021.
7
Maintenance Treatment With Low-Dose Decitabine After Allogeneic Hematopoietic Cell Transplantation in Patients With Adult Acute Lymphoblastic Leukemia.成人急性淋巴细胞白血病患者异基因造血细胞移植后低剂量地西他滨维持治疗
Front Oncol. 2021 Aug 16;11:710545. doi: 10.3389/fonc.2021.710545. eCollection 2021.